OCTAGON Clinical Trial Information

The OCTAGON clinical study is a multicenter clinical study to evaluate the effects of glatiramer acetate on the retinal nerve fiber layer (RNFL) in the back of the eye and visual function in people with a recent first episode of acute optic neuritis (AON). The primary objective of the study is to determine whether glatiramer acetate reduces the amount of axonal loss in the optic nerve after a first event of AON.

The OCTAGON clinical study is seeking to enroll approximately 200 participants in the United States with a first episode of AON in one eye. Participants will receive 6 months of therapy in the study. Some patients will receive the active medication in a daily injection under the skin while others will receive placebo (an inactive substance) for 6 months in the same manner. Neither you nor your doctor will know if you are receiving glatiramer acetate or the placebo.

You will need to be evaluated and enrolled into the study within 9 days of the onset of AON. The OCTAGON clinical study is currently enrolling participants.

Please use the navigation menu to the left to access FAQs and Eligibility Criteria for the OCTAGON clinical study.